Hb EP

Hemoglobin Electrophoresis

Q: What is the difference between sickle cell disease and sickle cell trait?

Sickle cell disease (most commonly HbSS) occurs when a person inherits two copies of the sickle hemoglobin gene (one from each parent). On electrophoresis, HbS comprises 80–95% of hemoglobin, with the remainder being HbF and HbA2. These individuals experience chronic hemolytic anemia, pain crises, and organ damage. Sickle cell trait (HbAS) occurs when a person inherits one sickle gene and one normal gene—electrophoresis shows 55–60% HbA and 35–45% HbS. Trait carriers are generally healthy but can pass the gene to children.

Q: Can iron deficiency affect my hemoglobin electrophoresis results?

Yes. Iron deficiency can lower HbA2 levels, potentially masking beta-thalassemia trait where HbA2 would otherwise be elevated above 3.5%. If you have microcytic anemia and your doctor suspects both iron deficiency and thalassemia, iron stores should be replenished first, followed by repeat hemoglobin electrophoresis for accurate interpretation. This is particularly important for carrier screening during pregnancy.

Q: Why is newborn screening for hemoglobinopathies important?

Newborn screening identifies sickle cell disease and other severe hemoglobinopathies before symptoms develop, enabling early interventions that dramatically improve survival. Before universal screening, many children with sickle cell disease died from overwhelming pneumococcal sepsis in early childhood. Early identification allows prophylactic penicillin starting at 2 months, pneumococcal vaccination, parental education on splenic sequestration, and early enrollment in comprehensive sickle cell programs. Newborn hemoglobin patterns differ from adults because HbF is predominant at birth.

Hemograma completo

Última revisión: 7 de abril de 2026. Enfoque de fuentes: contexto estándar de interpretación de laboratorio, material médico de referencia y orientación clínica o de salud pública cuando corresponde.

¿Qué es Hemoglobin Electrophoresis?

Hemoglobin electrophoresis is a laboratory technique that separates and identifies different types of hemoglobin in a blood sample based on their electrical charge and mobility in an electric field. Normal adult blood contains primarily hemoglobin A (HbA, approximately 95–98%), with small amounts of hemoglobin A2 (HbA2, 2–3.5%) and hemoglobin F (HbF, <2%). Hemoglobin electrophoresis, along with complementary methods such as high-performance liquid chromatography (HPLC) and capillary electrophoresis, can detect abnormal hemoglobin variants (HbS, HbC, HbE, HbD, and others) and quantify the proportion of each hemoglobin type present.

This test is the definitive diagnostic tool for hemoglobinopathies—inherited disorders of hemoglobin structure or production. Hemoglobinopathies include structural variants (such as sickle cell disease caused by HbS and HbC disease) and thalassemias (characterized by reduced production of normal globin chains leading to elevated HbA2 or HbF). These are among the most common genetic disorders worldwide, with approximately 5% of the global population carrying a significant hemoglobin variant. Hemoglobin electrophoresis is used for diagnostic confirmation, newborn screening follow-up, carrier identification, and prenatal genetic counseling.

Por qué importa

Hemoglobin electrophoresis is essential for diagnosing sickle cell disease, thalassemia syndromes, and other hemoglobinopathies that collectively affect millions of people worldwide. In sickle cell disease (HbSS), identifying the hemoglobin pattern guides treatment decisions including hydroxyurea therapy, transfusion protocols, and eligibility for curative gene therapy or bone marrow transplant. In thalassemia, elevated HbA2 (>3.5%) is the hallmark of beta-thalassemia trait, while elevated HbF characterizes beta-thalassemia major/intermedia and hereditary persistence of fetal hemoglobin. Carrier identification is critical for genetic counseling—two carriers of sickle cell trait (HbAS) have a 25% chance of having a child with sickle cell disease with each pregnancy.

Rangos de referencia normales

Grupo	Rango	Unidad
Hemoglobin A (HbA)	95–98	%
Hemoglobin A2 (HbA2)	2.0–3.5	%
Hemoglobin F (HbF)	<2	%
Hemoglobin S (HbS)	0	%
Hemoglobin C (HbC)	0	%

Los rangos de referencia pueden variar entre laboratorios. Compara siempre tus resultados con los rangos proporcionados por tu laboratorio.

Qué significan los niveles altos de Hb EP

Causas comunes

Elevated HbA2 (>3.5%): beta-thalassemia trait, megaloblastic anemia, hyperthyroidism
Elevated HbF (>2%): beta-thalassemia major/intermedia, sickle cell disease (especially on hydroxyurea), hereditary persistence of fetal hemoglobin (HPFH), myelodysplastic syndromes
Presence of HbS: sickle cell disease (HbSS: 80–95% HbS) or sickle cell trait (HbAS: 35–45% HbS)
Presence of HbC: HbC disease (HbCC) or HbC trait (HbAC)
Presence of HbE: HbE disease or HbE/beta-thalassemia (common in Southeast Asia)

Posibles síntomas

Sickle cell disease: pain crises, anemia, fatigue, jaundice, splenic sequestration, stroke, acute chest syndrome
Beta-thalassemia major: severe anemia, failure to thrive, hepatosplenomegaly, skeletal deformities
Beta-thalassemia trait: usually asymptomatic with mild microcytic anemia
Sickle cell trait: usually asymptomatic; rare complications under extreme conditions
HbC disease: mild hemolytic anemia, splenomegaly

Qué hacer: Management depends on the specific hemoglobinopathy identified. Sickle cell disease requires comprehensive care including hydroxyurea (which increases HbF), pain management, infection prophylaxis, screening for organ damage, and potentially curative therapies (stem cell transplant, gene therapy). Beta-thalassemia major requires regular transfusions and iron chelation. Carriers (trait) require genetic counseling for family planning. All patients with significant hemoglobinopathies should be followed by a hematologist.

Qué significan los niveles bajos de Hb EP

Causas comunes

Decreased HbA: beta-thalassemia (reduced beta-globin production), hemoglobinopathies replacing HbA with variant hemoglobin
Low HbA2 (<2%): iron deficiency (can mask thalassemia trait), alpha-thalassemia, HbH disease

Posibles síntomas

Symptoms depend on severity and type of hemoglobinopathy
Iron-deficient thalassemia trait may present with microcytic anemia unresponsive to iron

Qué hacer: Decreased HbA with increased abnormal hemoglobins confirms a hemoglobinopathy—the specific pattern determines diagnosis and management. If HbA2 is low and iron deficiency is present, correct the iron deficiency first and repeat hemoglobin electrophoresis, as iron deficiency can suppress HbA2 and mask beta-thalassemia trait. For suspected alpha-thalassemia (which may have a normal electrophoresis in adults), molecular genetic testing for alpha-globin gene deletions is needed.

¿Cuándo se recomienda la prueba de Hb EP?

As follow-up to an abnormal newborn hemoglobin screen
When evaluating unexplained microcytic anemia that does not respond to iron therapy
For carrier screening before or during pregnancy, particularly in high-risk populations
When sickle cell disease or trait is suspected
To confirm a diagnosis of thalassemia
When a family member has a known hemoglobinopathy

Preguntas frecuentes

Sickle cell disease (most commonly HbSS) occurs when a person inherits two copies of the sickle hemoglobin gene (one from each parent). On electrophoresis, HbS comprises 80–95% of hemoglobin, with the remainder being HbF and HbA2. These individuals experience chronic hemolytic anemia, pain crises, and organ damage. Sickle cell trait (HbAS) occurs when a person inherits one sickle gene and one normal gene—electrophoresis shows 55–60% HbA and 35–45% HbS. Trait carriers are generally healthy but can pass the gene to children.

Yes. Iron deficiency can lower HbA2 levels, potentially masking beta-thalassemia trait where HbA2 would otherwise be elevated above 3.5%. If you have microcytic anemia and your doctor suspects both iron deficiency and thalassemia, iron stores should be replenished first, followed by repeat hemoglobin electrophoresis for accurate interpretation. This is particularly important for carrier screening during pregnancy.

Newborn screening identifies sickle cell disease and other severe hemoglobinopathies before symptoms develop, enabling early interventions that dramatically improve survival. Before universal screening, many children with sickle cell disease died from overwhelming pneumococcal sepsis in early childhood. Early identification allows prophylactic penicillin starting at 2 months, pneumococcal vaccination, parental education on splenic sequestration, and early enrollment in comprehensive sickle cell programs. Newborn hemoglobin patterns differ from adults because HbF is predominant at birth.

Biomarcadores relacionados

HgbHemoglobina MCVVolumen corpuscular medio MCHHemoglobina corpuscular media FeHierro sérico FerritinFerritina

Referencias y enfoque de revisión

Las páginas del glosario de biomarcadores son explicaciones educativas y deben interpretarse junto con los rangos de referencia y comentarios proporcionados por tu laboratorio y tu profesional de salud. Para conocer nuestros estándares editoriales y proceso de revisión, consulta nuestra Política editorial y nuestro Proceso de revisión de contenido.

¿Quieres analizar tus niveles de Hb EP?

Sube tus resultados de laboratorio para recibir un análisis instantáneo con IA de todos tus biomarcadores.

Subir resultados de laboratorio →

Aviso médico: Esta información es solo educativa y no sustituye el consejo, diagnóstico ni tratamiento médico profesional. Los rangos de referencia pueden variar entre laboratorios. Consulta siempre a tu profesional sanitario para interpretar tus resultados concretos.